2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The added benefit is that AbbVie is a "Dividend King," which means it has consistently paid and increased dividends for the ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

AbbVie’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.95 ...

AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price shot up 0.1% during trading on Friday after Citigroup raised their price target on the stock from $215.00 to $226.00. Citigroup currently has a ...